Blood Pressure Medications — Compared

Lisinopril is one of the most widely prescribed medications in the United States. As an ACE inhibitor, it blocks the angiotensin-converting enzyme that transforms angiotensin I into angiotensin II — a potent hormone that constricts blood vessels and raises blood pressure. By blocking this conversion, lisinopril relaxes blood vessels and reduces the heart's workload.

Unlike some ACE inhibitors, lisinopril is not a prodrug — it is active as-is, without requiring hepatic conversion. This makes it more predictable in patients with liver disease. Its once-daily dosing and availability as generic tablets at multiple strengths contribute to its widespread use.

The most common side effect is a persistent dry cough, which occurs in 10–15% of patients and is a class effect of ACE inhibitors (not specific to lisinopril). Patients who develop this cough are often switched to an ARB. A rare but serious complication is angioedema — rapid swelling of the face, lips, tongue, or throat — which requires immediate medical attention. Lisinopril is contraindicated in pregnancy.

Ramipril is a prodrug ACE inhibitor converted by the liver to its active form, ramiprilat. It is particularly notable for the landmark HOPE (Heart Outcomes Prevention Evaluation) trial, which demonstrated that ramipril significantly reduced the risk of heart attack, stroke, and cardiovascular death in high-risk patients who did not necessarily have reduced ejection fraction or symptomatic heart failure.

This finding expanded the clinical role of ACE inhibitors beyond treating hypertension or heart failure — ramipril is now used to reduce overall cardiovascular risk in appropriate patients. Side effects mirror the ACE inhibitor class: dry cough is common, hyperkalemia can occur, and angioedema is a rare but serious risk.

Losartan was the first ARB approved by the FDA (1995) and remains one of the most commonly prescribed. Rather than blocking the production of angiotensin II like ACE inhibitors do, losartan blocks the AT1 receptor where angiotensin II exerts its blood-pressure-raising effects. This distinction is clinically important: because bradykinin levels are not affected, losartan does not cause the persistent dry cough associated with ACE inhibitors.

Losartan has a pharmacological feature unique among ARBs: it mildly lowers uric acid levels by blocking renal uric acid reabsorption. This can be modestly beneficial for patients who also have gout or elevated uric acid, and distinguishes it from other ARBs. It is a prodrug, converted to an active metabolite (E-3174) with a longer half-life.

Telmisartan has the longest half-life of all ARBs — approximately 24 hours — which provides smooth, sustained blood pressure control throughout the day and into the following morning, when the risk of cardiovascular events is highest. This pharmacokinetic profile is a clinical advantage for adherence and sustained effect.

Telmisartan also has partial agonist activity at the PPAR-γ (peroxisome proliferator-activated receptor gamma) nuclear receptor, the same receptor targeted by thiazolidinedione diabetes medications like pioglitazone. This may confer modest metabolic benefits — improved insulin sensitivity, lipid profile effects — though the clinical significance remains an area of research rather than a primary treatment rationale.

Amlodipine is the most commonly prescribed calcium channel blocker and one of the most prescribed blood pressure medications overall. It belongs to the dihydropyridine subclass — medications that act primarily on vascular smooth muscle to relax blood vessels, with minimal direct effect on the heart's conduction system or rate.

Its exceptionally long half-life (35–50 hours) means that once-daily dosing provides stable blood levels with minimal peaks and troughs, and that missed doses are less disruptive than with shorter-acting medications. It can be safely stopped without a taper, unlike beta blockers or clonidine.

The most common side effect is peripheral edema — ankle swelling caused by the redistribution of fluid into the interstitial space as blood vessels dilate. This is often dose-dependent and can be reduced by combining amlodipine with an ACE inhibitor or ARB, which counteract the fluid shift.

Diltiazem and verapamil are non-dihydropyridine calcium channel blockers. Unlike amlodipine and nifedipine, which act primarily on blood vessels, these drugs also significantly affect the heart — slowing the heart rate and the speed of electrical conduction through the AV node. This makes them useful for controlling ventricular rate in atrial fibrillation and atrial flutter, in addition to treating hypertension and angina.

Because of their cardiac effects, they must never be combined with beta blockers except under specialist supervision — the combination can cause dangerous bradycardia (abnormally slow heart rate) or heart block. Verapamil is the more cardiac-depressant of the two and also carries a significant drug interaction burden as a potent CYP3A4 inhibitor.

Constipation is the most characteristic and common side effect of verapamil — it is frequently troublesome enough to limit long-term use. Diltiazem is somewhat better tolerated in this regard.

Metoprolol is one of the most frequently prescribed beta blockers, available in two distinct formulations with meaningfully different pharmacokinetics. Metoprolol tartrate (Lopressor) is an immediate-release form that peaks within 1–2 hours and generally requires twice-daily dosing. Metoprolol succinate (Toprol-XL) is an extended-release form with smoother once-daily blood levels — and crucially, the succinate formulation has proven mortality benefit in heart failure with reduced ejection fraction.

Both forms are beta-1 selective — they preferentially block beta-1 receptors in the heart rather than beta-2 receptors in the lungs, making them safer than non-selective beta blockers in patients with asthma or COPD, though caution is still warranted at higher levels.

Carvedilol is a non-selective beta blocker that also blocks alpha-1 adrenergic receptors. This dual mechanism means it both slows the heart and dilates blood vessels — a combination that is particularly beneficial in heart failure with reduced ejection fraction, where carvedilol has robust mortality-reducing evidence (COPERNICUS trial).

The alpha-1 blocking activity also means carvedilol tends to cause more first-dose dizziness and hypotension than beta-1 selective agents, particularly when starting or increasing the strength. Taking it with food slows absorption and reduces peak drug levels, which substantially reduces dizziness — this is a clinical instruction your prescriber will emphasize.

Hydrochlorothiazide (HCTZ) is one of the oldest blood pressure medications still in widespread use and is probably the most commonly prescribed diuretic for hypertension. It works by blocking sodium and chloride reabsorption in the distal convoluted tubule of the kidney, which increases urine output and reduces blood volume, thereby lowering blood pressure.

HCTZ is frequently used in combination products alongside ACE inhibitors, ARBs, or calcium channel blockers — allowing patients to take one pill instead of two. Key metabolic side effects include hypokalemia (low potassium, which can affect heart rhythm), mild elevation in blood sugar and uric acid, and increased cholesterol. Electrolytes should be monitored periodically.

Spironolactone is a mineralocorticoid receptor antagonist — it blocks the effects of aldosterone, a hormone that causes the kidneys to retain sodium and excrete potassium. By blocking aldosterone, spironolactone promotes sodium and water excretion while retaining potassium, making it a "potassium-sparing" diuretic. This is in contrast to thiazides and loop diuretics, which cause potassium loss.

Spironolactone has become a cornerstone of treatment for resistant hypertension — blood pressure that remains elevated despite three or more medications at adequate levels. Adding spironolactone as a fourth agent produces meaningful additional BP reduction in many such patients (PATHWAY-2 trial). It is also used in heart failure with reduced ejection fraction, where it reduces mortality.

Hydralazine is a direct arterial vasodilator — it relaxes the smooth muscle of arterioles independently of receptor systems, causing blood vessels to widen and blood pressure to fall. It does not act on veins, which means it can cause reflex tachycardia as the body responds to arterial dilation by increasing heart rate.

Hydralazine is one of the few antihypertensives considered acceptable during pregnancy, where ACE inhibitors and ARBs are absolutely contraindicated. It is also used intravenously for hypertensive emergencies and, in combination with isosorbide dinitrate, as an alternative heart failure regimen for patients who cannot tolerate ACE inhibitors or ARBs (the BiDil combination is FDA-approved specifically for Black patients with heart failure).

Long-term use at higher levels can cause a lupus-like syndrome (drug-induced lupus), characterized by joint pain, rash, and elevated ANA antibody levels — this resolves after stopping the medication.

Clonidine works centrally in the brain — it activates alpha-2 adrenergic receptors in the brainstem that reduce sympathetic nervous system outflow. The result is a lower heart rate and relaxed blood vessels, without the peripheral mechanisms of most other antihypertensives. This central action also underlies clonidine's use in managing opioid withdrawal symptoms and ADHD (under the brand Kapvay).

Because clonidine acts on the central nervous system, sedation and dry mouth are among the most common and troublesome side effects. The transdermal patch formulation (applied weekly) provides steadier blood levels and is often better tolerated than tablets.

Lotrel combines amlodipine (a calcium channel blocker) and benazepril (an ACE inhibitor) in a single capsule. This combination is clinically rational: the two drugs work through complementary mechanisms, and the ACE inhibitor component actually helps reduce the ankle swelling that is amlodipine's most common side effect by counteracting the fluid redistribution that dihydropyridine CCBs cause.

Single-pill combinations like Lotrel are used when a patient's blood pressure is not controlled on either drug alone, and combining them in one capsule reduces pill burden and can improve adherence. Numerous other fixed-dose combinations exist (ACE+diuretic, ARB+CCB, ARB+diuretic) for the same rationale.